| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF00195139 |
| P698 | PubMed publication ID | 8751138 |
| P2093 | author name string | A K Daly | |
| P2860 | cites work | The GSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung | Q72828860 |
| Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics | Q72927887 | ||
| Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis | Q73554499 | ||
| Pharmacogenetics of alcohol metabolism and alcoholism | Q22242782 | ||
| Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase | Q22254865 | ||
| Genetic polymorphism of human cytochrome P-450 (S)-mephenytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency | Q24298532 | ||
| Human liver dehydroepiandrosterone sulfotransferase: molecular cloning and expression of cDNA | Q24301890 | ||
| Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants | Q24305540 | ||
| Human liver estrogen sulfotransferase: identification by cDNA cloning and expression | Q24314381 | ||
| Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans | Q24323988 | ||
| Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines | Q24339615 | ||
| Human cytochrome P-450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10 | Q24339638 | ||
| A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase | Q24563229 | ||
| cDNA and amino acid sequences of two members of the human P450IIC gene subfamily | Q24631075 | ||
| A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles | Q24672583 | ||
| Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity | Q24674721 | ||
| Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of [...] | Q28115162 | ||
| Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer | Q28118282 | ||
| Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells | Q41307358 | ||
| Inheritance of human platelet thermolabile phenol sulfotransferase (TL PST) activity | Q41395094 | ||
| Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors | Q41463151 | ||
| Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily | Q41578273 | ||
| Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily | Q41750193 | ||
| Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. | Q41828306 | ||
| The human phenolsulphotransferase polymorphism is determined by the level of expression of the enzyme protein | Q41839923 | ||
| Variability of acetaminophen metabolism in Caucasians and Orientals | Q42025095 | ||
| Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities | Q42052805 | ||
| Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism | Q42250456 | ||
| Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. | Q42281878 | ||
| Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. | Q42694246 | ||
| Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism | Q42834608 | ||
| Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test | Q43201721 | ||
| Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism | Q43531554 | ||
| Association between Restriction Fragment Length Polymorphism of the Human Cytochrome P450IIE1 Gene and Susceptibility to Lung Cancer | Q43904565 | ||
| Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. | Q43927814 | ||
| Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population | Q44115646 | ||
| Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk | Q44293824 | ||
| A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer | Q44629192 | ||
| Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility | Q44696853 | ||
| Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia | Q44917795 | ||
| Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. | Q46049355 | ||
| Identification of the primary gene defect at the cytochrome P450 CYP2D locus | Q48250898 | ||
| The molecular basis of the human serum paraoxonase activity polymorphism. | Q52542904 | ||
| Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. | Q53016262 | ||
| Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin | Q53025508 | ||
| Human polymorphism in drug metabolism: mutation in the dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. | Q53467377 | ||
| Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. | Q53470242 | ||
| Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. | Q53474186 | ||
| Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. | Q53477786 | ||
| Human glutathione S-transferase mu (GST mu) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. | Q53482957 | ||
| Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. | Q53489724 | ||
| Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. | Q53490047 | ||
| Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers | Q53491507 | ||
| Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. | Q53496846 | ||
| Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. | Q54216734 | ||
| High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase genes | Q54985963 | ||
| Urinary glucuronide excretion of fenofibric and clofibric acid glucuronides in man. Is it polymorphic? | Q57997223 | ||
| Metabolic oxidation phenotypes as markers for susceptibility to lung cancer | Q59082319 | ||
| Expression of Cytochrome-P450-3A5 in Escherichia Coli: Effects of 5′ Modification, Purification, Spectral Characterization, Reconstitution Conditions, and Catalytic Activities | Q59153257 | ||
| A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype | Q60705920 | ||
| An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution | Q63241981 | ||
| Mutant debrisoquine hydroxylation genes in Parkinson's disease | Q63241990 | ||
| Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients | Q64916964 | ||
| Pharmacogenetics of tolbutamide metabolism in humans | Q67017361 | ||
| Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes | Q67232854 | ||
| Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease | Q67516972 | ||
| Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities | Q67599101 | ||
| Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes | Q67652737 | ||
| Identification of the “major” polymorphic carbocysteine metabolite as S-(carboxymethylthio)-l-cysteine | Q67758541 | ||
| Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population | Q67809023 | ||
| Interindividual variability of coumarin 7-hydroxylation in healthy volunteers | Q67837226 | ||
| Structure of human estrogen and aryl sulfotransferase gene. Two mRNA species issued from a single gene | Q28240889 | ||
| Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese | Q28241420 | ||
| Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver | Q28243581 | ||
| The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans | Q28254348 | ||
| Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy | Q28255501 | ||
| Identification of an A-to-G missense mutation in exon 2 of the UGT1 gene complex that causes Crigler-Najjar syndrome type 2 | Q28258092 | ||
| Identification of two human brain aryl sulfotransferase cDNAs | Q28262159 | ||
| Sequence analysis and expression of the cDNA for the phenol-sulfating form of human liver phenol sulfotransferase | Q28265524 | ||
| Molecular characterisation of a human aryl sulfotransferase cDNA | Q28268657 | ||
| N-acetyltransferase | Q28270778 | ||
| Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily | Q28271091 | ||
| The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes | Q28281124 | ||
| Mechanisms of inherited deficiencies of multiple UDP‐glucuronosyltransferase isoforms in two patients with Crigler‐Najjar syndrome, type I | Q28286095 | ||
| Primary structures and properties of two related forms of aryl sulfotransferases in human liver | Q28290822 | ||
| Human Platelet Phenolsulfotransferases: cDNA Cloning, Stable Expression in V79 Cells, and Identification of a Novel Allelic Variant of the Phenol-Sulfating Form | Q28298682 | ||
| Polymerase chain reaction-directed identification, cloning, and quantification of human CYP2C18 mRNA | Q28299067 | ||
| Biochemistry and molecular biology of the human CYP2C subfamily | Q28299258 | ||
| The molecular biology of the flavin-containing monooxygenases of man | Q28300051 | ||
| Nomenclature for N-acetyltransferases | Q28302652 | ||
| Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects | Q28322217 | ||
| Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome | Q28324425 | ||
| Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine | Q28331073 | ||
| Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9 | Q28335592 | ||
| Impaired oxidation of debrisoquine in patients with perhexiline neuropathy | Q28366143 | ||
| Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine | Q28609999 | ||
| Biochemistry and genetics of monoamine oxidase | Q30420505 | ||
| Homozygous deletion of gene for glutathione S-transferase M1 in bladder cancer. | Q30445553 | ||
| Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I | Q31145683 | ||
| Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism | Q33245041 | ||
| Genetic Linkage of Lung Cancer-Associated MspI Polymorphisms with Amino Acid Replacement in the Heme Binding Region of the Human Cytochrome P450IA1 Gene1 | Q33269439 | ||
| Heterologous expression of the allelic variant mu-class glutathione transferases mu and psi. | Q33583775 | ||
| Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans | Q33899650 | ||
| Genetic polymorphism for human platelet thermostable phenol sulfotransferase (TS PST) activity | Q33955645 | ||
| Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype | Q67911285 | ||
| Paradoxical relationship between acetylator phenotype and amonafide toxicity | Q68034189 | ||
| Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia | Q68092294 | ||
| Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine | Q68204605 | ||
| Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity | Q69562919 | ||
| Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences | Q69783205 | ||
| The human serum paraoxonase/arylesterase polymorphism | Q69836522 | ||
| Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe | Q70552798 | ||
| Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls | Q70577046 | ||
| Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus | Q70583957 | ||
| The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma | Q70691847 | ||
| Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers | Q70702408 | ||
| Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver | Q70738005 | ||
| Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects | Q70780403 | ||
| A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype | Q70905284 | ||
| Deficient metabolism of debrisoquine and sparteine | Q71141001 | ||
| Variation in human metabolism of S-carboxymethylcysteine | Q71238173 | ||
| An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis | Q71365940 | ||
| Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone | Q71612339 | ||
| Polymorphisms of human Ah receptor gene are not involved in lung cancer | Q71721217 | ||
| Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase | Q71852856 | ||
| Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis | Q71895813 | ||
| Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation | Q71940148 | ||
| Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9 | Q71996232 | ||
| Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population | Q72113258 | ||
| Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls | Q72176950 | ||
| Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine | Q72207766 | ||
| Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient | Q72209986 | ||
| Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6 | Q72216677 | ||
| Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese | Q72293605 | ||
| Lack of a genetic polymorphism in the glucuronidation of fenofibric acid | Q72293610 | ||
| Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe | Q72293614 | ||
| Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms | Q72313196 | ||
| Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver | Q72371152 | ||
| A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine | Q72519987 | ||
| Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation | Q72545136 | ||
| Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood | Q72556670 | ||
| Human liver dehydroepiandrosterone sulfotransferase: nature and extent of individual variation | Q72561475 | ||
| A phenylalanine codon deletion at the UGT1 gene complex locus of a Crigler-Najjar type I patient generates a pH-sensitive bilirubin UDP-glucuronosyltransferase | Q72571462 | ||
| Cloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon | Q72640324 | ||
| Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation | Q72648752 | ||
| Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene | Q72701476 | ||
| Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity | Q72703173 | ||
| Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity | Q72703179 | ||
| Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype | Q72781679 | ||
| Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population | Q72800543 | ||
| Defective N-oxidation of sparteine in man: A new pharmacogenetic defect | Q34053243 | ||
| Polymorphic hydroxylation of Debrisoquine in man. | Q34057031 | ||
| Noninvasive tests of CYP3A enzymes | Q34059919 | ||
| Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes | Q34083456 | ||
| Identification of two single base substitutions in the UGT1 gene locus which abolish bilirubin uridine diphosphate glucuronosyltransferase activity in vitro | Q34124730 | ||
| Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. | Q34228651 | ||
| The clinical pharmacology of 6-mercaptopurine | Q34265967 | ||
| Existence of multiple forms of microsomal epoxide hydrolases with radically different substrate specificities | Q34266391 | ||
| Human dehydroepiandrosterone sulfotransferase gene: molecular cloning and structural characterization | Q34308132 | ||
| Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions | Q34323071 | ||
| Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan | Q34346859 | ||
| Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity | Q34346940 | ||
| A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine | Q34358854 | ||
| The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study | Q34358893 | ||
| Interindividual variability in the N-sulphation of desipramine in human liver and platelets | Q34402512 | ||
| Genetic and environmental factors that regulate cytosolic epoxide hydrolase activity in normal human lymphocytes | Q34580452 | ||
| Genetic Polymorphisms in the 5′-Flanking Region Change Transcriptional Regulation of the Human Cytochrome P450IIE1 Gene1 | Q34677484 | ||
| A Taq I polymorphism in the human P450IIE1 gene on chromosome 10 (CYP2E). | Q34729809 | ||
| Cosegregation of intragenic markers with a novel mutation that causes Crigler-Najjar syndrome type I: implication in carrier detection and prenatal diagnosis | Q35195055 | ||
| The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene | Q35197475 | ||
| The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site | Q35198610 | ||
| The role of individual human cytochromes P450 in drug metabolism and clinical response | Q35206070 | ||
| The novel bilirubin/phenol UDP-glucuronosyltransferase UGT1 gene locus: implications for multiple nonhemolytic familial hyperbilirubinemia phenotypes | Q35223429 | ||
| Identification of a genetic alteration in the code for bilirubin UDP-glucuronosyltransferase in the UGT1 gene complex of a Crigler-Najjar type I patient | Q35603726 | ||
| Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae | Q35877286 | ||
| Metabolic polymorphisms affecting activation of toxic and mutagenic arylamines | Q36327595 | ||
| Nucleotide sequence of a human liver cytochrome P-450 related to the rat male specific form | Q36420938 | ||
| Altered coding for a strictly conserved di-glycine in the major bilirubin UDP-glucuronosyltransferase of a Crigler-Najjar type I patient | Q36715577 | ||
| Drug glucuronidation in humans | Q36964610 | ||
| Genetic heterogeneity of the human glutathione transferases: a complex of gene families | Q37789537 | ||
| Phenytoin: pharmacogenetic polymorphism of 4'-hydroxylation | Q37924759 | ||
| Sulfotransferase pharmacogenetics | Q38140212 | ||
| Genetic polymorphism of trimethylamine N-oxidation | Q38140229 | ||
| UDP-glucuronosyltransferases | Q38234360 | ||
| DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers | Q38303763 | ||
| Genetic polymorphism of S-mephenytoin hydroxylation | Q38692055 | ||
| Methyltransferase pharmacogenetics | Q38692057 | ||
| An updated review of the clinical development of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin | Q39398936 | ||
| Glutathione transferases--structure and catalytic activity | Q39566893 | ||
| Molybdenum hydroxylases as drug-metabolizing enzymes | Q39834873 | ||
| Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene | Q40426578 | ||
| Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. | Q40498861 | ||
| Mspl polymorphism of the human CYP2E gene | Q40508074 | ||
| An XmnI RFLP detected with a probe for the CYP2E gene locus on chromosome 10. | Q40517031 | ||
| GST1 gene deletion determined by polymerase chain reaction | Q40517842 | ||
| Genetically variable metabolism of antidepressants and neuroleptic drugs in man. | Q40710734 | ||
| Pharmacogenetic phenotyping and genotyping. Present status and future potential. | Q40730354 | ||
| Metabolic polymorphisms | Q40840745 | ||
| Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. | Q41142887 | ||
| Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer | Q72804213 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 539-553 | |
| P577 | publication date | 1995-11-01 | |
| P1433 | published in | Journal of Molecular Medicine | Q6295593 |
| P1476 | title | Molecular basis of polymorphic drug metabolism | |
| P478 | volume | 73 |
| Q34388472 | 1998 ASHG presidential address. Making genomic medicine a reality |
| Q57302808 | 3 The pharmacology of the cytochrome P450 enzyme system |
| Q38357424 | Biotransformation of xenobiotics in the human colon and rectum and its association with colorectal cancer |
| Q38496627 | CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants |
| Q47655039 | Cytochrome p450 1Al gene polymorphisms in patients with psoriatic arthritis |
| Q40504499 | Dapsone-induced agranulocytosis. The role of xenobiotic-metabolizing enzymes demonstrated by a case report |
| Q35876954 | Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms |
| Q44600103 | Does the CYP3A5*3 polymorphism affect in vivo drug elimination? |
| Q34424230 | Enzymatic Mechanisms Involved in Phenanthrene Degradation by the White Rot Fungus Pleurotus ostreatus |
| Q37326678 | Expression of CYP2A6, CYP2D6 and CYP4A11 Polymorphisms in COS7 Mammalian Cell Line. |
| Q34207652 | Genetic clues to the molecular basis of tobacco addiction and progress towards personalized therapy |
| Q37775981 | Genetic polymorphism in metabolism and host defense enzymes: implications for human health risk assessment |
| Q81543852 | Genetic polymorphism of CYP2C19 in Maharashtrian population |
| Q43949916 | Genetic polymorphism of cytochrome P450 1A1 (Cyp1A1) and glutathione transferases (M1, T1 and P1) among Africans |
| Q44801583 | Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions |
| Q74549948 | Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese |
| Q35753607 | Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers |
| Q33538523 | Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity |
| Q34093093 | How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. |
| Q34936720 | Immune-mediated drug-induced liver disease |
| Q33555327 | Investigating the Role of Plasma Glucose Concentration as a Phenotypic Marker for CYP2C9 Genetic Variants, in the Diabetic Population of Gujarat |
| Q57445890 | Making drug discovery a SN(i)P |
| Q43710026 | Manganese superoxide dismutase and cytochrome P450 1A1 genes polymorphisms in rheumatoid arthritis in Taiwan |
| Q33941950 | Pharmacogenetic screening for susceptibility to fetal malformations in women |
| Q73798847 | Pharmacogenetics and drug metabolism |
| Q33781271 | Pharmacogenetics of cytochromes P450. |
| Q28210286 | Pharmacogenomics: the promise of personalized medicine |
| Q34331552 | Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. |
| Q33533986 | Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. |
| Q26781923 | Stem Cell Strategies to Evaluate Idiosyncratic Drug-induced Liver Injury |
| Q32103802 | Summary of information on human CYP enzymes: human P450 metabolism data |
| Q55474895 | The effect of anticonvulsant drugs on blood levels of methotrexate. |
| Q34232382 | The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis |
| Q41877081 | Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability |
| Q34311096 | Understanding the interaction between environmental exposures and molecular events in colorectal carcinogenesis |
Search more.